Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021…
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the…
On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of…
Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol®…
Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022YONKERS, N.Y., March…
$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash…
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and…
CHICAGO, March 24, 2022 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the Stifel 2022…
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical…
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announces the…